IV Ketamine Rapidly Effective in PTSD
Patients with moderate to severe post-traumatic stress disorder (PTSD) symptoms showed rapid and substantial relief with a single intravenous dose of ketamine in a pilot randomized trial, said researchers from the Icahn School of Medicine at Mount Sinai. In the first day after treatment, mean scores on the Impact of Event Scale-Revised (IES-R) fell to 14 from 46 at baseline following the IV ketamine infusion, whereas IV midazolam given to the same patients in the crossover trial led to a drop in IES-R scores from 48 to 25. The larger decline with ketamine versus midazolam was statistically significant, despite the small number of patients (29) who received both drugs, according to Mount Sinai’s Adriana Feder, MD, and colleagues writing in JAMA Psychiatry, who added “No emergence of significant psychotic or manic symptoms was observed.” The principal investigator for the study was Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai.
-Dr. Dennis S. Charney, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, President for Academic Affairs, Mount Sinai Health System,
-Dr. Adriana Feder, Associate Professor, Psychiatry, Icahn School of Medicine at Mount Sinai